U.S. Stem Cell, Inc. (USRM)

OTCMKTS: USRM · Delayed Price · USD
+0.0001 (2.08%)
Mar 20, 2023, 12:00 AM EDT - Market closed
Market Cap 3.11M
Revenue (ttm) 118,484
Net Income (ttm) -3.03M
Shares Out 634.40M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 386,712
Open 0.0054
Previous Close 0.0048
Day's Range 0.0048 - 0.0054
52-Week Range 0.0030 - 0.0120
Beta -0.66
Analysts n/a
Price Target n/a
Earnings Date n/a

About USRM

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-der... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 15, 2008
Country United States
Stock Exchange OTCMKTS
Ticker Symbol USRM
Full Company Profile

Financial Performance

In 2021, U.S. Stem Cell's revenue was $200,749, a decrease of -27.55% compared to the previous year's $277,087. Losses were -$3.29 million, 13.7% more than in 2020.

Financial Statements


Mark Borman Appointed Chairman of the Board of USRM

SUNRISE, FL / ACCESSWIRE / March 9, 2022 / U.S. Stem Cell, Inc. (OTC PINK:USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutio...

1 year ago - Accesswire